NCT06615596ToborozKorai 1. fázis
Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation
Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation: DESTINATION Study
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jún. 4.
Rövid összefoglaló (regiszter, angolul)
The DESTINATION Study investigates whether anticoagulation therapy is necessary after successful catheter ablation (CA) for atrial fibrillation (AF). Current guidelines recommend continued anticoagulation based on stroke risk scores, even post-ablation, potentially exposing patients to unnecessary bleeding risks. This international, multicenter, randomized controlled trial aims to compare thromboembolic and bleeding event risks between patients who continue and discontinue anticoagulation after ablation. The study involves 3,160 AF patients, all free of AF recurrence within 6 months to 1 year after ablation. Smart wearable monitors will track recurrence, and patients are followed for 24 months to assess event rates. Findings may reshape anticoagulation guidelines, improving clinical practice for AF patients worldwide.
- Állapot (regiszter)
- Toboroz
- Fázis (regiszter)
- Korai 1. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 3160 (tervezett)
- Első benyújtás
- 2024. szept. 22.
- Kezdés
- 2025. aug. 5.
- Elsődleges befejezés
- 2029. jan. 1.
- Fő szponzor
- China National Center for Cardiovascular Diseases
- Betegségek
- Pitvarfibrilláció
- NCT-szám
- NCT06615596
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · Korai 1. fázis
- Tervezett résztvevők: 3160
- 2025. aug. 5. és az elsődleges befejezés (2029. jan. 1.) között
- 12 helyszín, 2 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Prior AF ablation (including surgical ablation)
- Concomitant surgical ablation
- Patient has other contraindication to oral anticoagulation or treatment with antiplatelet agent
- Patient has been on strong CYP3A inducers (such as rifampicin, phenytoin, phenobarbital, or carbamazepine) or strong CYP3A inhibitors (such as ketoconazole or protease inhibitors) within 4 days of enrolment
Más betegség
- Valvular AF (moderate- severe mitral insufficiency; relevant mitral stenosis with a mean pressure gradient \>5mmHg)
- History of left atrial appendage occlusion/ligation/excision
- Patient has a non-arrhythmic condition necessitating long-term oral anticoagulation (i.e. PE, ventricular thrombus, peripheral thrombosis, etc)
- Recent myocardial infarction, NYHA class IV heart failure, patent foramen ovale, recent trauma or other prothrombotic conditions
- Patient with special risk factors for stroke unrelated to AF, specifically known thrombophilia/ hypercoagulability, uncontrolled hypertension (systolic blood pressure \>180 mmHg and/or diastolic blood pressure \>100 mmHg within 4 days of enrollment), untreated familial hyperlipidemia, known vascular anomaly (intracranial aneurysm/ arteriovenous malformation or chronic vascular dissection), or known severe carotid disease.
- Patient has bleeding contra-indication to oral anticoagulation (such as bleeding diathesis, hemorrhagic disorder, significant gastrointestinal bleeding within 6 months, intracranial/intraocular/ atraumatic bleeding history, fibrinolysis within 48 hours of enrollment).
- Structural congenital heart disease
- Recent stroke or intracranial hemorrhage within 6 months
- Inability to adequately understand nature, significance, implications and risks of study precipitation and to comply with follow-up (i.e. bipolar disorders, severe depression, suicidal tendencies, among others) as judged by the local physician, ongoing drug or alcohol addiction (\> 8 drinks/week)
Életkor
- Women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study
- Patients who are \> 85 years of age
Egyéb
- Reversible AF (e.g. uncontrolled hyperthyroidism)
- Left atrial diameter \>50 mm
- Left atrial or LAA thrombus
- Pregnancy/breast feeding
- Patients who are critically ill or who have a life expectancy \<3 years
- Patient is unable or unwilling to provide informed consent
- Patient is included in another randomized clinical trial or a clinical trial requiring an insurance
Kiket keres a vizsgálat
- Age ≥18 years
- Diagnosed paroxysmal, persistent, or longstanding persistent AF
- Successful procedure (defined as restoration of sinus rhythm after PV isolation for paroxysmal AF, restoration of sinus rhythm after PV isolation and completion of additional ablation for persistent AF, according to 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation) and no recurrence within 3 months of ablation, using a cooled tip RF-, laser- or cryo-balloon-catheter
- No periprocedural complications
- Signed informed consent
- Male with CHA2DS2-VASC score ≥1, female with score ≥2.
Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (12)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Fuwai Hospital | Beijing | Kína | Toboroz |
| Beijing Anzhen Hospital | Beijing | Kína | Toborzás még nem indult |
| West China Hospital,Sichuan University | Chengdu | Kína | Toborzás még nem indult |
| The First Affiliated Hospital, Sun Yat-sen University | Guangzhou | Kína | Toborzás még nem indult |
| Sir Run Run Shaw Hospital Zhejiang University School of Medicine | Hangzhou | Kína | Toboroz |
| Yunnan Fuwai Cardiovascular Hospital | Kunming | Kína | Toborzás még nem indult |
| Shanghai Chest Hospital | Shanghai | Kína | Toborzás még nem indult |
| Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen | Shenzhen | Kína | Toboroz |
| Shanxi Cardiovascular Hospital (Shanxi Cardiovascular Research Institute) | Taiyuan | Kína | Toborzás még nem indult |
| Wuhan Asia Heart Hospital | Wuhan | Kína | Toboroz |
| Fuwai Central China Cardiovascular Hospital | Zhengzhou | Kína | Toborzás még nem indult |
| Brigham and Women Hospital | Boston | Egyesült Államok | Toborzás még nem indult |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.